References
- 1. Adamson PC. Improving the outcome for children with cancer: development of targeted new agents. CA Cancer J Clin. 2015;65: 212-220.
- 2. A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of Cobimetinib In Pediatric And Young Adult Patients With Previously Treated Solid Tumors. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004685-25 Accessed 20JAN2017.
- 3. A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051). https://clinicaltrials.gov/ct2/show/NCT02332668 (Accessed 20JAN2017).
- 4. A Study to Determine Safety, Tolerability and Pharmacokineticsof Oral Dabrafenib In Children and Adolescent Subjects. https://clinicaltrials.gov/ct2/show/NCT01677741 (Accessed 20JAN2017).
- 5. Boots I, Sukhai RN, Klein RH, et al. Stimulation programs for pediatric drug research - do children really benefit? Eur J Pediatr. 2007; 166: 849-855.
- 6. BRIM-P. A study of Vemurafenib in pediatric patients with stage IIIC or stage IV melanoma harboring BRAFV600 mutations. https://clinicaltrials.gov/ct2/show/NCT01519323 (Accessed 20JAN2017).
- 7. Chitnis T, Tenembaum S, Banwell B et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012 Jan;18(1):116-2710.1177/1352458511430704
- 8. Eichler I, Sala Soriano E. Close collaboration between academia, industry and drug regulators is required in the development of allergen products for specific immunotherapy in children. Allergy 2011: 66: 999-1004.
- 9. EMA website. www.ema.europa.eu (Accessed 20JAN2017)
- 10. EMA 2004: Evidence of harm from off-label or unlicensed medicines in children. www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500004021.pdf
- 11. EMA 2011. EMA class waivers, http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/12/WC500119981.pdf (Accessed 20FEB2017).
- 12. EMA 2010. European Medicines Agency decision P/345/2010 of 20 December 2010 on a class waiver on condition(s) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/11/WC500011500.pdf. Accessed 20JAN2017 (Accessed 20JAN2017).
- 13. EMA 2015. European Medicines Agency decision CW/0001/2015 of 23 July 2015 on class waivers, in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council. www.ema.europa.eu/docs/en_GB/document_library/Other/2015/07/WC500190385.pdf
- 14. EMA 2015. Better Medicines for Children. www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2009/12/WC500026493.pdf
- 15. EMA2016. 10-year Report to the European Commission. General report on the experience acquired as a result of the application of the Paediatric Regulation. http://ec.europa.eu/health//sites/health/files/files/paediatrics/2016_pc_report_2017/ema_10_year_report_for_consultation.pdf. Accessed 20JAN2017 (Accessed 20JAN2017).
- 16. FDA. Best Pharmaceuticals for Children Act and Pediatric Research Equity Act July 2016. Status Report to Congress. www.fda.gov/downloads/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch/UCM509815.pdf (Accessed 20JAN2017).
- 17. Frattarelli DA, Galinkin JL, Green TP et al. Off-label Use of Drugs in Children. Pediatrics 2014, 133 (3), 563-567.
- 18. Hilts PJ. Protecting America›s Health: The FDA, Business, and One Hundred Years of Regulation. University of North Carolina Press 2004.
- 19. Kearns GL, Abdel-Rahman SM, Alander SW et al. Developmental Pharmacology - Drug Disposition, Action, and Therapy in Infants and Children. N Engl J Med. 2003;349(12):1157-1167.
- 20. Mentzer D. Progress review of the European Paediatric Regulatory Framework after six years of implementation. Int J Pharm. 2014 Aug 5;469(2):240-3.
- 21. Phase 2 study of Ipilimumab in children and adolescents (12 to < 18 Years) with previously treated or untreated, unresectable stage III or stage lV malignant melanoma. https://clinicaltrials.gov/ct2/show/NCT01696045.
- 22. Philip AG. The Evolution of Neonatology. Pediatr Res. 2005 Oct;58(4):799-815.
- 23. Regulation (EC) No 1901/2006 Of The European Parliament And Of The Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union, 27.12.2006, L 378/1 - L 278/19 http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdfpdf (Accessed 20JAN2017).
- 24. Rocchi F, Paolucci P, Ceci A, Rossi P. The European paediatric legislation: benefits and perspectives. Italian Journal of Pediatrics 2010, 36:56 Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933611/pdf/1824-7288-36-56.pdf (Accessed 20JAN2017).
- 25. Rose K. Pediatric Pharmaceutical Legislation in the USA and EU and Their Impact on Adult and Pediatric Drug Development. In: Bar-Shalom D & Rose K: Pediatric Formulations - A Roadmap, AAPS & Springer, 2014: chapter 28, pp. 405-420.
- 26. Rose K. European Union Pediatric Legislation Jeopardizes Worldwide, Timely Future Advances in the Care of Children With Cancer. Clinical Therapeutics 2014, 36 (2), 163-177.10.1016/j.clinthera.2014.01.009
- 27. Rose K. New Drugs For Rare Diseases in Children. Clin Ther 2017, in press.
- 28. Rose K & Happle R. The Impact of Regulation on Pediatric Psoriasis Drug Approvals: The Challenge of the European Union (EU) Pediatric Investigation Plans. Pediatric Dermatology 2017, in press.
- 29. Rose K & Kopp MV. Pediatric investigation plans for specific immunotherapy: Questionable contributions to childhood health. Pediatr Allergy Immunol. 2015 Dec;26(8):695-701.
- 30. Rose K & Mueller T. Children with Multiple Sclerosis Should Not Become Therapeutic Hostages. Ther Adv Neurol Disord 2016, 9(5) 389-395.10.1177/1756285616656592
- 31. Rose K & Walson PD. The contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemia. Risk Manag Healthc Policy. 2015 Nov 5;8:185-205.
- 32. Rose K & Walson PD. Do the European Medicines Agency (EMA) Decisions Hurt Pediatric Melanoma Patients? Clin Ther 2017, in press.10.1016/j.clinthera.2017.01.009
- 33. Rose K & Senn S. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee - adolescents’ melanoma as a paradigm. Pharmaceutical Statistics 2014; 13(4): 211-213.10.1002/pst.1623
- 34. Shim KS. Pubertal growth and epiphyseal fusion. Ann Pediatr Endocrinol Metab. 2015 Mar;20(1):8-12.
- 35. Shirkey H. Therapeutic Orphans. Pediatrics 1999 Sep;104(3 Pt 2):583-584.
- 36. To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT01962103 (Accessed 20JAN2017).
- 37. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards. Acta Paediatr 1999, 88: 965-968.